- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04836949
Verification of Shear Wave Elastography for DEtection of Prostate Cancer
- Objective To provide evidence that adding shear wave elastography during sono-guided prostate biopsy can increase prostate cancer detection rate and to demonstrate that shear wave elastography of the prostate can discriminate malignant lesions to reduce the number of unnecessary prostate biopsies.
Overview Patients who are indicated for prostate biopsy in suspicion of prostate cancer will be assigned to a control group and an intervention group under double blinded randomization.
- Control group : Patients will undergo prostate biopsy guided by conventional ultrasonography (B mode, gray scale).
- Experimental group : Patients will undergo prostate biopsy guided by shear wave elastography in addition to conventional ultrasonography.
A comparative statistical analysis of the two groups will be performed.
The study is planned to be conducted for 3 years, with 2 years for patient enrollment and 1 year of follow-up. Three hospitals will participate in the study to enroll 85 patients for each group and a total of 170 patients.
3. Inclusion and Exclusion criteria
Male patients with suspected prostate cancer must meet at least one of the following three criteria.
- PSA level over 4ng/dl
- Suspicious hard prostatic nodule on digital rectal examination.
- Hypoechoic lesion on ultrasound of the prostate suspicious for cancer.
Patients who (1) are less than 20 years old, (2) have a history of surgery on the prostate such as HoLEP, (3) have moderate cognitive impairment, or (4) have medical conditions precluding transrectal procedures such as rectal cancer are excluded from the study.
4. Research method
- Patients who wish to participate in this study and meet the inclusion/exclusion criteria are randomly assigned to the 2 groups as described above.
The biopsy results are checked one week after the procedure.
- Patients confirmed to have prostate cancer are provided proper treatment according to generally accepted treatment methods.
- Patients with negative biopsy results are followed according to general follow-up protocol for suspected prostate cancer patients. After 6 months from the biopsy the patients are re-evaluated and if cancer is still suspected based on PSA level or other clinical symptoms, prostate MRI or additional biopsy is be performed.
- Patients are followed again after 12 months since the initial biopsy with identical methods from the 6 months follow-up protocol.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Woong Kyu Han
- Numéro de téléphone: 82-2-2228-2310
- E-mail: hanwk@yuhs.ac
Lieux d'étude
-
-
-
Seoul, Corée, République de
- Yonsei University Health System, Severance Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- PSA level over 4ng/dl
- Suspicious hard prostatic nodule on digital rectal examination.
- Hypoechoic lesion on ultrasound of the prostate suspicious for cancer.
Exclusion Criteria:
- Less than 20 years old
- History of surgery on the prostate such as HoLEP
- More than moderate cognitive impairment which limits understanding of the study
- Medical conditions precluding transrectal procedures such as rectal cancer
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Shear Wave Elastography Group
|
A 12-core template biopsy is planned as during a conventional prostate biopsy.
The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas.
The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy.
Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
|
|
Comparateur actif: Conventional ultrasonography Group
|
A conventional 12-core template biopsy is planned.
The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas.
Random biopsy of each area is performed.
Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Detection rate of prostate cancer
Délai: The presence of prostate cancer on pathologic results is checked one to two weeks after the biopsy.
|
The number of subjects diagnosed with prostate cancer and the rate of detection by each group.
|
The presence of prostate cancer on pathologic results is checked one to two weeks after the biopsy.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Woong Kyu Han, Severance Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1-2020-0072
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .